Vertex Pharmaceuticals Incorporated (VRTX) AI Stock Analysis

Vertex Pharmaceuticals Incorporated develops and commercializes therapies targeting specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its marketed portfolio features SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA for cystic fibrosis. Beyond CF, Vertex advances a clinical pipeline that includes VX-864 for alpha-1 antitrypsin deficiency in Phase 2, VX-147 for APOL1-mediated kidney diseases in Phase 2, VX-880 for Type 1 Diabetes in Phase 1/2, VX-548 for acute and chronic pain in Phase 2, and CTX001 for severe sickle cell disease and transfusion-dependent thalassemia in Phase 3. The company collaborates with partners such as CRISPR Therapeutics, Moderna, and Affinia Therapeutics.

Vertex delivered a 5-year revenue CAGR of 14.2% from FY2020 to FY2025. Annual revenue expanded from $7.57B in FY2021 to $12.07B in FY2025. While FY2024 showed an operating margin of -2.1% and net income of -$535.6M, performance recovered in FY2025 with an operating margin of 39.4% and net income of $3.95B. Gross margin was 85.0% in FY2025, down from 88.1% in FY2021. Over the trailing twelve months ended June 30, 2026, revenue reached $12.59B with a profit margin of 35.0%. In the latest quarter ended June 30, 2026, quarterly revenue grew 12.5% year-over-year while quarterly earnings rose 8.0%.

As of June 30, 2026, Vertex held $7.85B in cash and short-term investments against $1.98B in total debt, yielding a net cash position of $5.87B. The company maintains strong liquidity with a current ratio of 3.19 and a debt-to-equity ratio of 0.10 against $20.25B in shareholders' equity. In FY2025, operating cash flow reached $3.63B and free cash flow was $3.19B. Capital allocation that year included $437.6M in capital expenditures and $2.02B in share buybacks, with share count decreasing 0.5% over 5 years.

Vertex closed at $499.74 on October 16, 2026, representing a market cap of $126.66B and an enterprise value of $125.00B. The stock trades at a trailing P/E of 28.9x, below the median of its Nasdaq-100 Healthcare peers of 34.1x, while its forward P/E of 24.1x sits above the peer median of 19.7x. Its price-to-sales ratio is 10.1x compared to the peer median of 6.5x, and EV/EBITDA is 24.5x versus 20.9x. Over the past 1 year, VRTX gained 22.3% compared to 16.8% for the S&P 500 (SPY), and over 5 years it returned 174.9% against 83.0% for the index.

Wall Street analysts display a positive stance on Vertex, with 20 Strong Buy, 6 Buy, 5 Hold, 0 Sell, and 1 Strong Sell ratings. The mean price target is $571.46, implying an upside of 14.4% from the last close of $499.74. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $13.27B and EPS of $17.83, a decline of 3.1%. Vertex beat EPS estimates in 3 of the last 4 quarters. The next earnings date is November 2, 2026.

This page is an AI-written research summary of Vertex Pharmaceuticals Incorporated (VRTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VRTX income statement, VRTX balance sheet, VRTX key metrics, VRTX analyst forecast, VRTX chart. See the VRTX stock overview for the latest quote and news.